This study examined the time course and possible mechanisms of agonist-induced desensitization of 5-hydroxytryptamine serotonin 2A receptors in the rat frontal cortex and hypothalamic paraventricular nucleus after 1, 4, and 7 days of treatment with (Ϫ)-1-(2,5-dimethoxy-4-iodophenyl)2-aminopropane HCl [(Ϫ)-DOI] (1 mg/kg i.p.), a selective 5-HT 2A/2C receptor agonist. In the frontal cortex, 5-HT-mediated phospholipase C (PLC) enzyme activity decreased by 24 to 30% after 4 to 7 days of (Ϫ)-DOI treatment without any significant changes in the guanosine 5Ј-3-O-(thio)triphosphate-mediated PLC enzyme activity. Additionally, treatment with (Ϫ)-DOI did not significantly change the levels of G ␣11 , regulator of G protein signaling (RGS)4, or RGS7 proteins in the frontal cortex, whereas G ␣q protein levels in the frontal cortex decreased (47%) only after 7 daily (Ϫ)-DOI injections. The functional status of 5-HT 2A receptors in the hypothalamic paraventricular nucleus was examined using 5-HT 2A receptor-mediated increases in plasma hormone levels. Plasma adrenocorticotrophic hormone (ACTH) and oxytocin measurements showed that 5-HT 2A receptor desensitization began after only 1 day of (Ϫ)-DOI treatment, and the desensitization continued to increase after 4 and 7 days of treatment (ACTH response decreased 64.2-67.7%; oxytocin response decreased 82.3-90.1%). There were no significant alterations in levels of G ␣q or G ␣11 proteins in the hypothalamic paraventricular nucleus. In conclusion, these results suggest that chronically administered (Ϫ)-DOI induces desensitization of 5-HT 2A receptors in vivo, via a reduction in the ability of 5-HT 2A receptors to activate G proteins without consistently altering levels of G ␣ proteins or RGS proteins.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.